ACTH 1-17 effects in the chemotherapy of advanced solid tumors

Carlo Barone, Antonio Grieco, Antonio Astone, Loredana Vagliviello, Carlo Garufi, Aldo Virgilio Greco

Research output: Contribution to journalArticlepeer-review


The effect of administration of a synthetic ACTH analogue (ACTH 1-17, Synchrodyn®) in the chemotherapy of advanced-phase solid tumors was studied. In this preliminary report the following data are evaluated: response rate; occurrence of toxic effects; performance status of patients; several immunological parameters. The administration of Synchrodyn® seems mainly to influence the lymphocyte subpopulations and the occurrence of toxic effects. A final evaluation of the role that may be played by chronotherapy in the treatment of tumors must await further studies on the clinical response and tolerance.

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalLa Ricerca in Clinica e in Laboratorio
Issue number2
Publication statusPublished - Apr 1984


  • ACTH
  • Chemotherapy
  • Chronotherapy
  • Immunocomplexes
  • Lymphacytes subpopulations

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'ACTH 1-17 effects in the chemotherapy of advanced solid tumors'. Together they form a unique fingerprint.

Cite this